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Induction of Upregulation and
Downregulation of the T-Cell Activation
Marker CD98 in Patients Undergoing
Contrast-Enhanced CT with Iodinated 
Non-Ionic Dimeric Contrast Medium
Objective: This study was designed to determine prospectively the expression
of the multifunctional CD98 protein in peripheral white blood cells in patients
receiving iodinated contrast media (CM) for a computed tomography (CT) exami-
nation.
Materials and Methods: In 12 adult patients that received non-ionic dimeric
CM (iosimenol or iodixanol), the expression of CD98 was analyzed from samples
of peripheral white blood cells obtained prior to, one hour, and 24 hours after CM
injection by the use of flow cytometry analysis and the use of the direct immuno-
fluorescence technique.
Results: Overall, expression of CD98 was significantly downregulated 24
hours after CM injection (51.9%±10.8% vs. 38.8%±16.9%; p < 0.04). Patients
that received iosimenol exhibited a more pronounced but not significant decrease
of CD98 expression both one hour and 24 hours after CM injection. In an analysis
of specific patient responses, CD98 downregulation occurred in eight patients. In
two patients, CD98 was upregulated, and in the remaining two patients, expres-
sion remained unchanged. No patient acquired an adverse CM reaction.
Conclusion: This is the first demonstration that CM may be a regulator of
CD98 expression. To determine if upregulation is associated with an increased
risk for the acquisition of an adverse CM-induced hypersensitivity reaction and if
downregulation is associated without a risk for the acquisition of an adverse CM-
induced hypersensitivity reaction, further studies with a larger population of
patients are required.
lthough the use of iodinated X-ray contrast media (CM) has been shown
to be safe in patients, the use of CM can induce hypersensitivity reactions
in a small percentage of patients that may occur immediately or may be
delayed (1-8). Immediate hypersensitivity reactions, whether allergic or non-allergic in
nature, are mediated by biogenic amines such as histamine and tryptase that are
released by basophils and/or mast cells and are clinically characterized by anaphylaxis
(urticaria, angioedema, laryngeal edema, bronchial constriction and occasionally
cardiac arrest and loss of awareness). On the contrary, both non-immediate drug
reactions in general and CM reactions in particular are primarily T-cell hypersensitiv-
ity reactions (1, 9-11) that are immunohistologically detectable in patients with such
manifestations (12, 13). Histopathological findings are nonspecific and cannot be
distinguished from other drug reactions (13). Therefore, T-cell reactivity has been
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Aassessed by proliferation in response to the drug with use
of the lymphocyte transformation test (9, 10) or by the
ability to enhance the expression of activation molecules
such as CD69 (9-11). 
The heterodimeric L-type amino acid transporter 1
(LAT1/CD98), initially described as early T-cell activation
marker, has been shown to exert multiple cell functions
including cell adhesion and cell fusion (14-18). Moreover,
LAT1/CD98 vectorially transports both drugs (e.g.
pregabalin) and 3-iodo-α -methyl-L-tyrosine across the cell
membrane into the cell (19-21). It is currently question-
able if iodinated CM that are intravenously injected for
enhanced computed tomography (CT) are able to influence
the expression of CD98 in circulating white blood cells.
Therefore, the goal of this study was to determine the
expression of the CD98 protein in peripheral blood cells in
patients that received two different non-ionic dimeric
contrast agents and to determine if CD98 expression was
upregulated or downregulated.
METHODS AND MATERIALS
Subjects
This study was performed in 12 adult patients (males, n =
8) who underwent diagnostic CT examination. All subjects
participated in a clinical double-blinded trial that evaluated
the frequency and type of CM-induced side effects by
comparing the use of non-ionic dimeric CM iosimenol and
iodixanol. The local ethics committee approved the study.
Patients provided informed consent for the study and for
blood/serum sampling. Adult patients were included (i)
that were not receiving immunosuppressive drugs (e.g.
glucocorticosteroids, azathioprine, cyclophosphamide) or
antihistamines, (ii) who had undergone their last therapeu-
tic radiation therapy and/or chemotherapeutic cycle more
than six weeks prior and (iii) who had no history of
previous CM side effects. The mean patient age was 55.3
years (age range, 45-64 years). Blood samples were
collected prior to, one hour and 24 hours after CM
injection by the use of sterile venipuncture.
Contrast Media
Dimeric iodixanol (Visipaque; GE Healthcare, Freiburg,
Germany) and dimeric iosimenol (Interpharma, Prague,
Czech Republic) were supplied as sterile, aqueous solutions
of 270 mg I/mL (osmolality of -300 mosm/kg) or 280 mg
I/mL (osmolality of -300 mosm/kg), respectively. The
chemical structures of both compounds are shown in
Figure 1. The CM were injected intravenously at a rate of
2 ml/sec. The patients were administered 100 ml of either
iodixanol or iosimenol.
Flow Cytometry
Peripheral blood mononuclear cells (PBMC) were
separated by the use of Ficoll-Hypaque (Biochrom, Berlin,
Germany) density gradient centrifugation and were stained
with direct phycoerythrin (PE)-, fluorescein isothiocyanate
(FITC)- or peridinin chlorophyll protein (PerCP)-
conjugated mAbs. Appropriate isotype control antibodies
and anti-CD3 (mouse IgG1, clone SK7), anti-CD4 (mouse
IgG1, clone SK3), anti-CD8 (mouse IgG1, clone SK1), anti-
CD45 (mouse IgG1, clone 2D1), anti-HLA-DR (mouse
IgG1, clone L243), anti-CD14 (mouse IgG2a, clone TUK4)
and anti-CD98 (mouse IgG1, clone 4F2) were purchased
from Becton-Dickinson (Mountain View, CA). For each
sample, 10,000 events were acquired, the data were stored
and then analyzed by the use of FACScan Research
software (CellQuest, Becton Dickinson).
Immunofluorescence analysis was performed by the use of
dot plot and histogram analysis. Values were expressed as
the percentage of the gated total lymphocyte population.
Statistical Analysis
Data are expressed as mean±standard deviation. The
normal distribution of the investigated subsets was
demonstrated by use of the Kolmogorov-Smirnov test.
Significance of differences between means was calculated
using the Student’s t-test for paired and unpaired data.
Statistical analysis of different groups was conducted using
the ANOVA-test with Bonferroni correction for multiple
comparisons. The Chi-squared test was used to test the
differences in the frequency of adverse reactions in
patients that received iosimenol and iodixanol. Differences
between values were considered statistically significant at p
< 0.05.
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Fig. 1. Chemical structure of iosimenol (upper panel) and
iodixanol (lower panel).RESULTS
Modulation of the CD98 Expression under the
Influence of Contrast Media Injection 
We first analyzed the ability of CM-administration on
the overall expression of CD98 in peripheral blood
lymphocytes. We found a decrease both at one hour and at
24 hours after CM injection (Figs. 2, 3A).
Effects of the Two Dimeric Contrast Agents
In patients that received iosimenol, a decrease of the
CD98 expression was detected both after one hour and
after 24 hours (Fig. 3). The decrease in expression after 24
hours was more pronounced than after one hour. In
patients that received iodixanol, CD98 expression initially
decreased after one hour and then increased (Fig. 3). The
differences between CD98 expression in patients that
received either iosimenol or iodixanol were not statistically
different.
Different Individual Patient Regulation of CD98 and
Acquisition of a Contrast Media Induced Adverse
Reaction 
In most patients (n = 8, 5 males) CM Injection induced
downregulation of CD98 expression. In two patients that
received iodixanol (1 male and 1 female), upregulation of
CD98 occurred and in two other patients (2 males) CM
injection did not induce any CD98 expression change.
To determine if upregulation or downregulation might
correspond to an allergic reaction cannot be answered in
the present investigation as none of patients acquired an
unwanted side effect. In a large patient study population
(80 patients; 65 males), 10% of patients that received
iosimenol (males:females = 3:1) and 8% of patients (all
males) that received iodixanol acquired non-immediate
reactions (data not shown). This difference was not statisti-
cally significant (p > 0.06).
DISCUSSION
The goal of the present study was to determine if
injection of dimeric non-ionic contrast agents (iosimenol
and iodixanol) under routine conditions in patients
undergoing a CT examination is able to affect the expres-
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Fig. 2. Representative fluorescence microscopy of peripheral
white blood cells expressing CD98 after staining with monoclonal
anti-CD98 antibody labelled with FITC (fluorescein isothio-
cyanate).
Fig. 3. Modulation of the CD98 expression under the influence of contrast media injection.
A. Contrast media injection in patients that received iosimenol and iodixanol induced non-significant decrease of CD98 expression after
one hour and significant decrease of CD98 expression in peripheral lymphocytes after 24 hours (*p < 0.04). 
B. CD98 expression in lymphocytes (%) ± standard deviation prior to and at one hour and at 24 hours after injection of either iosimenol
(left diagram) or iodixanol (right diagram). Decrease of CD98 expression in patients that received iosimenol was significant after 24 hours
(**p < 0.05). 
ABsion of the T-cell activation molecule CD98 in PBMC. We
found that dimeric CM injection has the pharmacological
ability to induce either upregulation or downregulation of
CD98.
CD98 (also known as 4F2 antigen and 125 kDa N-
glycosylated type II transmembrane glycoprotein) is the
heavy chain of the heterodimeric amino acid transport
system (HAT) that is expressed in almost all cell types
except platelets (15-18, 22-25). The HAT is composed of
two polypeptides: a heavy subunit that is covalently associ-
ated with one of different light chains (also called LAT1,
LAT2). The light chain is the transporter and the heavy
chain is required for the functional cell surface expression
and localization of the HAT complex (25). CD98 initially
identified as an activation marker molecule has diverse
cellular functions such as amino acid transport, cell
adhesion (i.e. integrin beta1 function), migration and
perhaps polarization (17, 22-25), and is implicated in the
regulation of cellular differentiation, adhesion, growth and
apoptosis (15).
Previously, it has been shown that IFN-gamma mediates
the transcriptional regulation of CD98 (23), but its regula-
tion seems to be independent of the interleukin
2/interleukin 2 receptor system (14). Upregulation of
CD98 expression also occurs during lymphocyte activation
induced by mitogens, superantigens, conventional antigens
and a combination of phorbol myristate acetate and
ionomycin (14). Several substances inhibit the expression
of CD98 such as rolipam, a potent and selective phospho-
diesterase inhibitor (26). Similar results have been
obtained with the use of pentoxifylline. This agent has a
significant inhibitory effect on the T lymphocyte expres-
sion of the activation antigens CD25 (IL-2R alpha-chain),
CD69 (activation-inducer molecule), and CD98 (4F2)
induced by phytohaemagglutinin (27). Dimeric contrast
agents seem either to inhibit or to enhance the expression
of CD98. Since both injected contrast agents are of blood
iso-osmolality, this physico-chemical property did not seem
responsible for the observed changes in CD98 expression.
Although both compounds are dimeric non-ionic contrast
agents of a similar chemical structure (Fig. 1), they induced
different CD98 expression patterns one hour and 24 hours
after CM injection (Fig. 3B). Moreover, it was remarkable
that dimeric non-ionic CM administration can either
upregulate or downregulate the CD98 cell surface
receptor. In addition, in some patients, expression of CD98
did not change after intravenous CM injection.
Interestingly, expression of CD98 is increased in allergic
patients (28). The increased risk for these patients to
acquire an adverse CM-induced reaction might be a result
of increased CD98 expression. Although from the preset
study it is not possible to draw general conclusions, it is
tempting to speculate that downregulation of CD98
expression that occurred in most patients might be associ-
ated with no risk for hypersensitivity while upregulation of
this activation marker could be a sign for an increased risk
for the acquisition of such a reaction.
The transport-related proteins BAT and 4F2hc are not
specific for amino acids and can mediate the cross
membrane transport of a variety of other agents such as
uridine, pyruvate, thyroid hormone and drugs such as
pregabalin, and melphalan (20, 21, 24, 29, 30). From the
present study it is not possible to determine if the CD98
protein mediates the transport of iodinated CM. However,
both the thyroid hormone and 3-iodo-α -methyl-L-tyrosine
transport is mediated by heterodimers of the 4F2 heavy-
chain (19, 20) and it is well established that traces of free
iodine present in iodinated contrast agents solutions
interfere with the physiological iodine thyroid uptake
competitively in the thyroid hormone transport system.
The main limitation of this study is that no patient
exhibited a hypersensitivity reaction. Therefore, it would
be necessary to investigate this activation marker in
patients who have a positive history of a CM-related non-
immediate hypersensitivity. Another limitation of the
presented trial is the lack of a control population that
received saline injection instead of the contrast agent to
exclude other factors that could influence CD98 regula-
tion. The study environment or the injection procedure
could theoretically induce modification of CD98 expres-
sion. Therefore, in future studies, additional control
subjects need to be employed.
In conclusion, we have provided for the first time
evidence that CM injection might influence the expression
of the CD98 protein. The current study is a preliminary
proof of concept. CD98 is an immunological activation
marker and if CM-induced upregulation of CD98 expres-
sion contributes to adverse hypersensitivity reactions is still
unclear. To address this question in more detail, an investi-
gation with a larger patient population is warranted.
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